Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.33% $0.370
America/New_York / 28 mar 2024 @ 12:16
FUNDAMENTALS | |
---|---|
MarketCap: | 3.12 mill |
EPS: | -7.60 |
P/E: | -0.0500 |
Earnings Date: | Mar 31, 2024 |
SharesOutstanding: | 8.43 mill |
Avg Daily Volume: | 0.410 mill |
RATING 2024-03-27 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0500 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -0.0500 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.311 - 0.427 ( +/- 15.72%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Mahery Amy | Buy | 12 420 | Option to purchase common stock |
2024-02-01 | Gumulka Jerzy | Buy | 33 333 | Series B Warrant to purchase common stock |
2024-02-01 | Gumulka Jerzy | Buy | 33 333 | Series A Warrant to purchase common stock |
2024-02-01 | Gumulka Jerzy | Buy | 33 333 | Common stock |
2024-02-01 | Evans Carl Anthony | Buy | 33 333 | Series B Warrant to purchase common stock |
INSIDER POWER |
---|
93.51 |
Last 86 transactions |
Buy: 3 691 286 | Sell: 2 431 436 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.370 (0.33% ) |
Volume | 0.0987 mill |
Avg. Vol. | 0.410 mill |
% of Avg. Vol | 24.06 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.